Lady Tata Memorial Trust International Awards

 

Previous Publications

The page displays the list of previous years' published journals. To view the published journals of a particular year, select the year from the drop down list and click on the button next to it.
Academic Year: Please select the Academic year from the list.
Please select scholarship from the list.

Published Journals of the Academic Year 2021 - 2022
Sr.No.Applicant NameJournal NameTitle Of PublicationAuthor NameCountry Name
1Dr Rita HleihelBloodRetinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells.El Hajj H, et alLebanon
2Dr Rita HleihelCancerImidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.Nabbouh AI*, Hleihel RS*, et alLebanon
3Dr Rita HleihelCancersLenalidomide in Combination with Arsenic Trioxide: an Effective Therapy for Primary Effusion Lymphoma.Moodad S*, El Hajj R*, Hleihel R*, et alLebanon
4Dr Rita HleihelFront MicrobiolMouse Models That Enhanced Our Understanding of Adult T Cell Leukemia.9. Moodad S, Akkouche A, Hleihel R, Darwiche N, El-Sabban M, Bazarbachi A, El Hajj H.Lebanon
5Dr Rita HleihelGenesA Critical Review of Animal Models Used in Acute Myeloid Leukemia Pathophysiology.7. Skayneh H*, Jishi B*, Hleihel R, Hamieh M, Darwiche N, Bazarbachi A, El Sabban M, El Hajj H.Lebanon
6Dr Rita HleihelMol Cancer Ther.Antitumor Effect of the Atypical Retinoid ST1926 in Acute Myeloid Leukemia and Nanoparticle Formulation Prolongs Lifespan and Reduces Tumor Burden of Xenograft Mice.10. El-Houjeiri L*, Saad W*, Hayar B*, et alLebanon
7Dr Rita HleihelOncogeneDisruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells.Kouzi F, et alLebanon
8Dr Rita HleihelRetrovirologyThe HTLV-1 oncoprotein Tax is modified by the ubiquitin related modifier 1 (Urm1).Hleihel R, Khoshnood B, et alLebanon
9Dr Celine PhilippeBiomoleculesER Stress and Unfolded Protein Response in Leukemia: Friend, Foe or Both?Philippe, C.*, Feral, K.*, Jaud, M.*,..., Rouault-Pierre, K., Mazzolini, L., Touriol, C.United Kingdom
10Dr Celine PhilippeCancersThe PERK Branch of the Unfolded Protein Response Promotes DLL4 Expression by Activating an Alternative Translation MechanismPhilippe, C.*, Jaud, M.*, ...Pyronnet, S., Laurell, H., & Touriol, C.United Kingdom
11Dr Celine PhilippeCellsTranslational Regulations in Response to Endoplasmic Reticulum Stress in CancersPhilippe, C.*, Jaud, M.*, ..., Rouault-Pierre, K., & Touriol, CUnited Kingdom
12Dr Celine PhilippeOncotargetKey contribution of eIF4H-mediated translational control in tumor promotionVaysse, C., Philippe, C., ...Brousset, P., Prats, H., & Touriol, CUnited Kingdom
13Dr Celine PhilippeScience SignallingPERK mediates the IRES-dependent translational activation of mRNAs encoding angiogenic growth factors after ischemic stressPhilippe, C.*, Dubrac, A.*, ...Prats, H., Brousset, P., & Touriol, C.United Kingdom
14Dr Ferran NadeuAnnual Review of Pathology: Mechanisms of DiseaseGenomic and epigenomic alterations in chronic lymphocytic leukemiaNadeu F, et al.Spain
15Dr Ferran NadeuBloodClinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemiaNadeu F, et al.Spain
16Dr Ferran NadeuBloodGenomic and epigenomic insights into the origin, pathogenesis and clinical behavior of mantle cell lymphoma subtypesNadeu F*, Martin-Garcia D*, et al.Spain
17Dr Ferran NadeuBloodIGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigeneticsNadeu F, et al.Spain
18Dr Ferran NadeuBloodMutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activationSchmidt J*, Ramis-Zaldivar JE*, Nadeu F, et al.Spain
19Dr Ferran NadeuBlood Cancer JournalPatterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experienceMozas P, Nadeu F, et al.Spain
20Dr Ferran NadeuClinical Cancer ResearchMutational landscape and tumor burden assessed by cell-free DNA in diffuse large B-cell lymphoma in a population-based studyRivas-Delgado A*, Nadeu F*, et al.Spain
21Dr Ferran NadeuHaematologicaChronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategiesDelgado J, Nadeu F, et al.Spain
22Dr Ferran NadeuHaematologicaSerum monoclonal component in chronic lymphocytic leukemia: baseline correlations and prognostic impactMozas P*, Pineyroa JA*, Nadeu F, et al.Spain
23Dr Ferran NadeuLeukemiaClinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemiaNadeu F, et al.Spain
24Dr Ferran NadeuLeukemiaMinimal spatial heterogeneity in chronic lymphocytic leukemia at diagnosisNadeu F, et al.Spain
25Dr Ferran NadeuNAA complete list of my 39 publications can be found in GoogleScholar (user: Ferran Nadeu), ORCiD (0000-0003-2910-9440), or Publons (user: Ferran Nadeu).I have listed here the 15 publications were I have participated as a first, second or third author.Spain
26Dr Ferran NadeuNatureThe U1 spliceosomal RNA is recurrently mutated in multiple cancersShuai S*, Suzuki H*, Diaz-Navarro A*, Nadeu F, et al.Spain
27Dr Ferran NadeuNature CancerThe proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcomeDuran-Ferrer M, Clot G, Nadeu F, et al.Spain
28Dr Ferran NadeuNature CommunicationsA practical guide for mutational signature analysis in hematological malignanciesMaura F, Degasperi A, Nadeu F, et al.Spain
29Dr Ferran NadeuNature CommunicationsIgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasmsNadeu F, et al.Spain
30Mrs Anouchka LaurentBlood AdvancesPartial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine modelsPaola Rivera-Munoz*, Anouchka P. Laurent*, Aurelie Siret*, Cecile K. Lopez et al.United States
31Mrs Anouchka LaurentClinical Cancer ResearchConstitutive activation of RAS/MAPK pathway cooperates with trisomy 21 and is therapeutically exploitable in Down syndrome B cell precursor leukemiaAnouchka P. Laurent, Aurélie Siret, Cathy Ignacimouttou, et al.United States
32Mrs Anouchka LaurentLeukemiaGain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndromeAnouchka P. Laurent, Rishi S. Kotecha, Sébastien MalingeUnited States
33Mrs Anouchka LaurentThe Journal of Clinical InvestigationDYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3Rahul S Bhansali, Malini Rammohan, Paul Lee, Anouchka P Laurent et al.United States
34Dr Laura MosteobioRxiv (https://doi.org/10.1101/2020.10.26.350116)Loss of erythroblasts in acute myeloid leukemia causes iron redistribution with clinical implicationsLopes M, et al.Portugal
35Dr Laura MosteobioRxiv (https://doi.org/10.1101/2021.01.13.426554)BRN2 is a non-canonical melanoma tumor-suppressorHamm M, et al.Portugal
36Dr Laura MosteoFrontiers in Cell and Developmental Biology (https://doi.org/10.3389/fcell.2021.635189)The Dynamic Interface Between the Bone Marrow Vascular Niche and Hematopoietic Stem Cells in Myeloid MalignancyMosteo L, et al.Portugal
37Dr Laura MosteoOncogeneThe transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expressionJessen C, et al.Portugal
38Dr Laura MosteoRSC AdvancesPolarization, second-order nonlinear optical properties and electrochromism in 4H-pyranylidene chromophores with a quinoid/aromatic thiophene ring bridgeMarco BA, et al.Portugal
39Dr Laura MosteoTetrahedronInfluence of thiazole regioisomerism on second-order nonlinear optical chromophoresGalán E, et al.Portugal
Disclaimer   All right reserved @ copyright Lady Tata Memorial Trust 2012. Mininum resolution 1024 x 768.